<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24919" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Meige Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zeppieri</surname>
            <given-names>Marco</given-names>
          </name>
          <aff>University Hospital of Udine, Italy</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ameer</surname>
            <given-names>Muhammad Atif</given-names>
          </name>
          <aff>Suburban Community Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jahngir</surname>
            <given-names>Muhammad U.</given-names>
          </name>
          <aff>University of Missouri, Columbia</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Bhupendra C.</given-names>
          </name>
          <aff>University of Utah</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Marco Zeppieri declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Atif Ameer declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Jahngir declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Bhupendra Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>14</day>
          <month>5</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24919.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Meige syndrome, also known as Brueghel syndrome or idiopathic orofacial dystonia, is a rare neurological disorder characterized by involuntary muscle contractions leading to repetitive and stereotyped movements of the face, mouth, and neck.&#x000a0;Named after the French neurologist Dr Henry Meige, who initially reported the illness in 1910, Meige syndrome is classified as a type of movement disorder falling under dystonia. This condition is characterized by persistent or sporadic muscle contractions resulting in aberrant, frequently repetitive postures, motions, or both.&#x000a0;Individuals affected by Meige syndrome experience a wide array of complex symptoms, including involuntary blinking (blepharospasm) and spasms of the jaw muscles (oromandibular dystonia), which may progress gradually over time and significantly affect their quality of life.</p>
        <p>Management often involves a multidisciplinary approach, integrating medications, botulinum toxin injections, and supportive therapies to alleviate symptoms and enhance function. Treatment challenges arise due to the disorder's unpredictable course and its impact on daily functioning, often affecting speech, swallowing, and chewing muscles.&#x000a0;Understanding the complexities of Meige syndrome is vital for its effective diagnosis and management, providing hope for individuals affected by this challenging condition. This activity explores the clinical presentation, diagnostic criteria, current understanding of pathophysiology, and evidence-based management strategies for patients with Meige syndrome. This activity provides clinicians with comprehensive knowledge and skills to deliver optimal care while emphasizing the vital role of an interprofessional healthcare team in enhancing patient care and achieving optimal clinical outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify characteristic symptoms of Meige syndrome, including blepharospasm and oromandibular dystonia, through thorough patient history and physical examination.</p></list-item><list-item><p>Implement evidence-based treatment strategies tailored to individual patient needs, including medications, botulinum toxin injections, and surgical interventions.</p></list-item><list-item><p>Select appropriate therapeutic modalities based on patient preferences, treatment goals, and clinical evidence.</p></list-item><list-item><p>Collaborate&#x000a0;among interprofessional healthcare providers to optimize patient care and improve treatment efficacy and outcomes for patients with Meige syndrome.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24919&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24919">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24919.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Meige syndrome is a focal dystonic movement disorder characterized by blepharospasm (double eyelid spasm) and oromandibular dystonia.<xref ref-type="bibr" rid="article-24919.r1">[1]</xref> Dystonia involves abnormal involuntary posturing or body movements resulting from sustained muscle contractions, often arising from neurological or medical causes. In 1910, Dr Henry Meige, a French neurologist, observed abnormal contractions of midline facial muscles, including involuntary eyelid closure, in approximately 10 patients. He initially termed this condition "spasm facial median."<xref ref-type="bibr" rid="article-24919.r2">[2]</xref><xref ref-type="bibr" rid="article-24919.r3">[3]</xref> These patients also&#x000a0;demonstrated a similar clinical manifestation in the muscles of the jaw and oropharynx.</p>
        <p>In 1972, Dr George Paulson introduced the term "Meige syndrome" to describe patients experiencing facial muscle spasms, notably blepharospasm and dystonia of oromandibular muscles.<xref ref-type="bibr" rid="article-24919.r4">[4]</xref> After several years, Gilbert introduced the term "Brueghel syndrome" to describe a case of jaw dystonia, distinguished from Meige syndrome by the absence of blepharospasm.<xref ref-type="bibr" rid="article-24919.r5">[5]</xref><xref ref-type="bibr" rid="article-24919.r6">[6]</xref></p>
        <p>The use of the term "Meige syndrome" for a type of dystonia based on historical perspectives can be problematic and confusing, especially considering that this physician did not suffer from the syndrome and was not the first doctor to describe this type of dystonia.<xref ref-type="bibr" rid="article-24919.r4">[4]</xref> Medical associations, including the Council of Science Editors, have discouraged using possessive forms of eponyms.<xref ref-type="bibr" rid="article-24919.r7">[7]</xref><xref ref-type="bibr" rid="article-24919.r8">[8]</xref> Moreover, Meige syndrome is sometimes confused with Meigs' syndrome, which&#x000a0;is unrelated to dystonia and defines the clinical presentation found in a specific type of benign ovarian tumor.<xref ref-type="bibr" rid="article-24919.r9">[9]</xref></p>
        <p>Although the exact pathophysiology of Meige syndrome is unknown, it is believed to be related to abnormalities in the basal ganglia&#x02014;a critical brain region essential for motor control.<xref ref-type="bibr" rid="article-24919.r10">[10]</xref> Dystonia is thought to result from dysfunction in neurotransmitter systems, particularly affecting dopamine and gamma-aminobutyric acid (GABA).<xref ref-type="bibr" rid="article-24919.r11">[11]</xref></p>
        <p>The course of Meige syndrome varies significantly from person to person. Symptoms typically begin gradually and may worsen over time, although they can also enter spontaneous remission or remain stable. The age of symptom onset may also differ. Some&#x000a0;individuals experience symptoms in early adulthood, whereas others may not exhibit them until later in life. Managing and treating symptoms can be challenging due to their unpredictable nature and influence on day-to-day functioning.<xref ref-type="bibr" rid="article-24919.r12">[12]</xref></p>
        <p>The lower face and jaw are typically the initial areas to exhibit signs of Meige syndrome. These signs manifest as involuntary spasms of the muscles involved in speech, swallowing, and chewing. Eventually, dystonic movements can extend to the lips, tongue, cheeks, and neck muscles, among other parts of the face.<xref ref-type="bibr" rid="article-24919.r13">[13]</xref>&#x000a0;In some&#x000a0;cases, dystonia may extend to different parts of the body, resulting in generalized dystonia, while in others, it remains confined to the oromandibular region.</p>
      </sec>
      <sec id="article-24919.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Primary Meige syndrome manifests without an identifiable underlying cause and is typically&#x000a0;characterized by isolated dystonic movements in the face and jaw. In contrast, secondary Meige syndrome stems from identifiable triggers such as medications, neurodegenerative diseases, or structural brain lesions, often accompanied by additional neurological symptoms or signs indicative of the underlying cause.</p>
        <p>
<bold>Primary Meige Syndrome</bold>
</p>
        <p>Most Meige syndrome cases are classified as idiopathic, and the exact cause of the ailment is still unknown. However, several variables, including genetic, environmental, and neurochemical effects, have been linked to its pathophysiology.</p>
        <p>Hereditary factors have been reported to be possibly involved in this syndrome, with studies&#x000a0;indicating the significance of genetic components in generating the disease.<xref ref-type="bibr" rid="article-24919.r14">[14]</xref> Meige syndrome can occasionally run in families, which suggests a hereditary susceptibility to the condition. Clinical manifestations of Meige syndrome have been observed in patients with p.Gly213Ser or p.Ala353thr mutations. Recent findings suggest that mutations in the&#x000a0;<italic toggle="yes">GNAL</italic>&#x000a0;gene (which encodes the guanine nucleotide-binding protein G, subunit alpha) have been reported to cause cranial and cervical dystonia. However,&#x000a0;further evidence is required to confirm this association.<xref ref-type="bibr" rid="article-24919.r15">[15]</xref><xref ref-type="bibr" rid="article-24919.r16">[16]</xref></p>
        <p>Studies involving first-degree relatives of individuals with Meige syndrome have demonstrated a penetrance of approximately 20%, possibly indicating an autosomal dominant transmission.<xref ref-type="bibr" rid="article-24919.r17">[17]</xref> The&#x000a0;inheritance pattern is often complex, influenced by both environmental factors and multiple genes. Meige syndrome, along with other forms of dystonia, has been associated with mutations in&#x000a0;<italic toggle="yes">TOR1A</italic> (DYT1), <italic toggle="yes">THAP1</italic>, and <italic toggle="yes">GNAL&#x000a0;</italic>genes, which are involved in neurotransmitter control or neuronal excitability.<xref ref-type="bibr" rid="article-24919.r18">[18]</xref><xref ref-type="bibr" rid="article-24919.r19">[19]</xref></p>
        <p>
<bold>Secondary Meige Syndrome</bold>
</p>
        <p>Although hereditary factors may predispose individuals to Meige syndrome, environmental triggers can also influence the development or severity of symptoms. These triggers may include psychological stress, exposure to certain drugs or toxins, or physical trauma such as surgery or a brain injury.<xref ref-type="bibr" rid="article-24919.r20">[20]</xref> Although the exact mechanisms by which these environmental factors contribute to dystonia development remain unclear, interactions with genetic predisposition are believed to be involved.</p>
        <p>Dysfunction in the basal ganglia and associated neuronal circuits is a crucial component of the pathogenesis of Meige syndrome. Changes in the levels or activities of neurotransmitters, including glutamate, GABA, and dopamine, have been implicated in dystonia development, as these neurotransmitters are vital for controlling motor function. Individuals with dystonia, including those with Meige syndrome, often exhibit structural abnormalities or alterations in brain regions involved in motor control, such as the thalamus, sensorimotor cortex, and basal ganglia. Dystonic symptoms may arise from these anomalies, disrupting the normal functioning of motor circuits.</p>
        <p>Long-term use of neuroleptic medications, experienced by approximately one-fourth of patients, may lead to alterations in receptor function, resulting in facial or cervical dystonia. This denervation hypersensitivity is believed to be caused by increased central dopaminergic activity, supported by its improvement with dopamine-depleting agents. Medications that elevate central dopamine activity, such as antiemetics (eg, metoclopramide), antipsychotics, antidepressants, selective serotonin reuptake inhibitors, antihistamines, and dopaminergic agonists, can contribute to this condition. Various other factors, including head trauma, stroke, demyelination of the brain stem region, normal pressure hydrocephalus, cerebral hypoxia, postoperative bilateral thalamotomy, kernicterus, space-occupying lesions, and postencephalitis, have been implicated in the disorder's development.<xref ref-type="bibr" rid="article-24919.r20">[20]</xref> Meige syndrome can be associated with other movement disorders, such as Parkinson disease, Wilson disease, olivopontocerebellar atrophy, or Lewy body disease.<xref ref-type="bibr" rid="article-24919.r21">[21]</xref></p>
        <p>Comprehending the intricate interaction of genetic, environmental, and neurochemical elements involved in the genesis of Meige syndrome is essential for devising targeted treatment interventions to alleviate symptoms and improve the quality of life for affected individuals.</p>
      </sec>
      <sec id="article-24919.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Meige syndrome is relatively uncommon compared to other movement disorders. This condition presents with a wide range of clinical manifestations, typically characterized by segmental myodystonia leading to blepharospasm and abnormal muscular activity in the oromandibular and neck regions.<xref ref-type="bibr" rid="article-24919.r22">[22]</xref>&#x000a0;Patients with Meige syndrome are typically aged between 30 and 70, with a mean age of 55.7 years, although cases in teenagers have been reported.<xref ref-type="bibr" rid="article-24919.r23">[23]</xref> Studies indicate an average onset age in the sixth decade of life.<xref ref-type="bibr" rid="article-24919.r24">[24]</xref><xref ref-type="bibr" rid="article-24919.r25">[25]</xref>&#x000a0;Variable data regarding the prevalence of isolated blepharospasm and craniocervical dystonia are available, which are estimated to be around 2% to 20%.<xref ref-type="bibr" rid="article-24919.r26">[26]</xref> Studies based on crude estimates of the prevalence of blepharospasm and segmental dystonia range from 16 to 133 cases per million.<xref ref-type="bibr" rid="article-24919.r27">[27]</xref><xref ref-type="bibr" rid="article-24919.r28">[28]</xref></p>
        <p>The precise sex ratio of Meige syndrome varies across studies, although there appears to be a tendency for the disorder to affect females more frequently. Some research indicates a relatively equal distribution between sexes, while others suggest a female-to-male ratio of approximately 2:1.<xref ref-type="bibr" rid="article-24919.r29">[29]</xref> The higher prevalence in females may be attributed to unknown factors, possibly related to hormones, environmental influences, or genetics.<xref ref-type="bibr" rid="article-24919.r30">[30]</xref> Hypotheses suggest that specific estrogen receptors in females make them prone to involuntary muscle spasms.<xref ref-type="bibr" rid="article-24919.r31">[31]</xref></p>
        <p>Meige syndrome has been documented globally; however, the frequency of reporting and detection may differ based on factors such as geographical location, access to healthcare facilities, diagnostic capabilities, and awareness. Although extensive population-based research on the incidence of Meige syndrome is limited, case series and clinical reports from various countries across North America, Europe, Asia, and other continents have been reported. Studies conducted in the United States have reported prevalence estimates ranging from 13 to 130 individuals per million, while European studies have indicated estimates of approximately 36 individuals per million.<xref ref-type="bibr" rid="article-24919.r32">[32]</xref></p>
      </sec>
      <sec id="article-24919.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Meige syndrome is characterized by anomalies in the basal ganglia-thalamocortical motor circuitry,&#x000a0;leading to aberrant postures and involuntary muscular contractions, such as other kinds of dystonia. Current research suggests that aberrant sensory-motor integration, changes in cortical excitability, and malfunctioning neurotransmitter systems are among the possible pathophysiological causes underlying Meige syndrome, although these mechanisms are not fully elucidated.</p>
        <p>Dopamine, glutamate, and GABA are the 3 important neurotransmitters involved in controlling motor function within the basal ganglia-thalamocortical circuitry. The pathophysiology of Meige syndrome has been associated with dysregulation of several neurotransmitter systems. The prevailing hypothesis for the development of Meige syndrome involves dopaminergic and cholinergic hyperactivity, although it may also stem from the reduced function of inhibitory neurons, such as GABAergic neurons, in the cortex. Notably, dystonia is believed to arise from diminished dopamine signaling in the basal ganglia, particularly within the striatum.</p>
        <p>Dysfunction in the dopaminergic pathway can disrupt the balance between direct and indirect routes, leading to increased neuronal firing and abnormal muscle contractions.<xref ref-type="bibr" rid="article-24919.r33">[33]</xref> GABA is the brain's main inhibitory neurotransmitter, crucial for regulating neuronal excitability.<xref ref-type="bibr" rid="article-24919.r34">[34]</xref> Changes in GABAergic signaling, such as deficiencies in GABA production, release, or receptor function, may contribute to aberrant patterns of neuronal activity in the basal ganglia and cortical motor areas, exacerbating dystonic symptoms. Glutamate, the primary excitatory neurotransmitter in the central nervous system, mediates synaptic transmission within the basal ganglia-thalamocortical circuitry.<xref ref-type="bibr" rid="article-24919.r35">[35]</xref></p>
        <p>Various environmental and genetic factors&#x000a0;render a patient prone to craniocervical dystonia. Some researchers suggest that these patients exhibit abnormal sensorimotor processing, as evidenced by positron emission tomographic scans revealing decreased blood flow to the sensorimotor area in response to lower face vibrations. Silent functional magnetic resonance imaging (MRI) has shown reduced activation within the primary motor cortex (Brodmann area 4) and premotor cortex (Brodmann area 6) in the orofacial regions of Meige syndrome patients with isolated blepharospasm. This reduced activity may stem from disrupted regulation of cranial nerve nuclei in the brainstem by the basal ganglia. Brain imaging identifies a gray matter volume reduction in the cerebellum, superior frontal gyrus, insular cortex, and calcarine fissure in patients with craniocervical dystonia.<xref ref-type="bibr" rid="article-24919.r36">[36]</xref><xref ref-type="bibr" rid="article-24919.r37">[37]</xref></p>
        <p>Focal dystonias also exhibit a genetic component in their etiopathogenesis. At the cellular level, mutations in the<italic toggle="yes"> TOR1A</italic> gene appear to cause a disturbed exchange of vesicles into and out of the nucleus, which in turn&#x000a0;causes transcriptional dysregulation.<xref ref-type="bibr" rid="article-24919.r38">[38]</xref><xref ref-type="bibr" rid="article-24919.r39">[39]</xref> A&#x000a0;similar mechanism is implicated in other primary focal dystonias, such as mutations in central nervous system transcriptional factors such as <italic toggle="yes">TAF1</italic>&#x000a0;and <italic toggle="yes">THAP1</italic>.<xref ref-type="bibr" rid="article-24919.r40">[40]</xref>&#x000a0;Studies involving animal and human models show evidence of specific genetic mutations that may lead to the disrupted development of the neuronal network.</p>
      </sec>
      <sec id="article-24919.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The pattern of presentation of Meige syndrome varies among patients. Symptoms may initially manifest as unilateral blepharospasm before progressing to bilateral involvement (see <bold>Video.&#x000a0;</bold>Typical Blepharospasm). One of the most challenging aspects of Meige syndrome is its diverse phenotypic forms, which can range from tonic spasms or prolonged closure of the eye to complete inability to open the eyes. Eyelid weakness or blepharoptosis is also prevalent.<xref ref-type="bibr" rid="article-24919.r25">[25]</xref> This condition is characterized by progressive muscle dysfunction, typically beginning as focal neurological dysfunction such as essential blepharospasm or oromandibular dystonia before spreading to other muscle groups. Muscles of the neck (antecollis, retrocollis, and torticollis), respiratory muscles, or upper limb muscles (resulting in dystonic tremors) may become affected.<xref ref-type="bibr" rid="article-24919.r41">[41]</xref> Commonly involved oromandibular muscles include the temporalis, masseter, and platysma. Involuntary lower facial and masticatory movements may encompass lip pursing, chewing, grimacing, jaw thrusting, and opening or closing/clenching actions.<xref ref-type="bibr" rid="article-24919.r42">[42]</xref></p>
        <p>Patients frequently report a slow onset of symptoms, typically starting with occasional clenching of the jaw or facial twitching of the face. Over time, the frequency and intensity of involuntary movements and atypical postures may increase, indicating a progression of symptoms.<xref ref-type="bibr" rid="article-24919.r25">[25]</xref> Studies suggest that the likelihood of dystonic contractions spreading to adjacent muscle groups is highest within the first year of symptom onset, with this risk persisting for the subsequent 3 to 5 years. In individuals with blepharospasm, factors such as older age at onset, female gender, and a history of head trauma may elevate the risk of symptom spread.<xref ref-type="bibr" rid="article-24919.r43">[43]</xref></p>
        <p>Patients with Meige syndrome often use sensory tricks, which are sensory stimuli they learn to use to alleviate their dystonia symptoms. Common examples include sleeping, relaxing, talking, pulling the upper eyelid, blowing cheeks, walking, exposure to cold water, yawning, or drinking beverages.<xref ref-type="bibr" rid="article-24919.r44">[44]</xref> More than half of patients with blepharospasm utilize&#x000a0;1 or multiple&#x000a0;sensory tricks.<xref ref-type="bibr" rid="article-24919.r42">[42]</xref> Additionally, patients may identify specific behaviors (eg, speaking&#x000a0;and eating) or aggravating circumstances (eg, stress, exhaustion, and coffee) that exacerbate their symptoms. Recognizing these triggers can assist in treatment decisions and provide valuable insights into the pathophysiology of Meige syndrome.</p>
        <p>A thorough evaluation of a patient's medical history is essential for assessing their risk of Meige syndrome. This includes inquiring about any history of drug use, neurological issues, or prior head trauma. Additionally, a family history of dystonia or other movement disorders may suggest a genetic predisposition to the condition.</p>
        <p>The physical examination of individuals with Meige syndrome typically highlights characteristic clinical symptoms, including involuntary muscular spasms in the face, jaw, and neck. A comprehensive history and physical examination are essential to guide further evaluation and treatment. In addition, it is crucial to evaluate for associated symptoms, functional limitations, and potential triggers or exacerbating factors. A thorough neurological examination is indispensable for assessing reflexes, coordination, gait, motor function, and sensory trick function. Any presence of bradykinesia, tremors, dystonic movements, or other neurological symptoms warrants careful consideration for possible underlying neurological conditions.</p>
      </sec>
      <sec id="article-24919.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Assessing Meige syndrome is crucial for establishing a diagnosis, identifying potential underlying causes, and guiding treatment decisions. The evaluation of Meige syndrome involves a comprehensive approach, including clinical assessment, neuroimaging scans, and laboratory investigations. As Meige syndrome cannot be diagnosed with a single specific test, a thorough evaluation is essential to rule out other potential causes and determine the severity of the condition.</p>
        <p>Brain MRI plays a crucial role in ruling out structural abnormalities that may resemble or exacerbate dystonic symptoms, including tumors, vascular malformations, or other lesions.<xref ref-type="bibr" rid="article-24919.r45">[45]</xref> Although&#x000a0;brain MRI findings in Meige syndrome often appear normal, imaging can be valuable in certain cases to distinguish secondary causes of dystonia. Additionally, MRI and/or computed tomography (CT) of the brain can aid in ruling out stroke as a potential underlying cause.</p>
        <p>Electrophysiological investigations are valuable in the differential diagnosis of Meige syndrome. Nerve conduction studies and electromyography (EMG) can provide essential information regarding muscle activation patterns and help exclude other neuromuscular conditions that can be mistaken for dystonia.<xref ref-type="bibr" rid="article-24919.r46">[46]</xref> Surface EMG recordings are particularly useful for assessing the type and intensity of myofascial contractions in individuals with Meige syndrome.</p>
        <p>Genetic testing is a valuable consideration in cases where there is a family history of dystonia or suspected genetic predisposition.<xref ref-type="bibr" rid="article-24919.r47">[47]</xref>&#x000a0;Genes linked to dystonia, such as <italic toggle="yes">TOR1A (DYT1)</italic>, <italic toggle="yes">THAP1</italic>, and <italic toggle="yes">GNAL</italic>, may be the subject of targeted sequencing or panel testing to help identify pathogenic mutations that may be responsible for Meige syndrome.<xref ref-type="bibr" rid="article-24919.r32">[32]</xref><xref ref-type="bibr" rid="article-24919.r48">[48]</xref></p>
        <p>Metabolic and toxicological screening is valuable in cases with unusual symptoms or suspected secondary dystonia. Laboratory testing for metabolic diseases, such as Wilson disease or mitochondrial abnormalities, may be necessary. Additionally, investigating exposure to chemicals or drugs known to induce dystonia is essential. The workup should encompass a serum drug screen, SSA/SSB levels, Cu and ceruloplasmin levels, uric acid levels, and Beck's Depression Inventory.<xref ref-type="bibr" rid="article-24919.r49">[49]</xref></p>
        <p>The European Federation of Neurological Societies (EFNS), the American Academy of Neurology, and other international societies have published clinical recommendations in the literature for diagnosing and treating movement disorders. These guidelines provide valuable insights into diagnosing and managing Meige syndrome, drawing upon the latest research findings and best practices.<xref ref-type="bibr" rid="article-24919.r50">[50]</xref></p>
      </sec>
      <sec id="article-24919.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Meige syndrome care aims to alleviate symptoms, enhance functional outcomes, and improve the quality of life for affected individuals. Treatment approaches typically involve a combination of medications, botulinum toxin injections, surgical interventions, and supportive therapies.</p>
        <p>Various oral medications, including muscle relaxants, dopamine receptor antagonists, and anticholinergic drugs, are utilized to address dystonic symptoms in Meige syndrome.<xref ref-type="bibr" rid="article-24919.r51">[51]</xref> These medications aim to reduce muscle spasms and improve motor function, while individual differences in their effectiveness may exist.<xref ref-type="bibr" rid="article-24919.r52">[52]</xref> Understanding the pathophysiology of Meige syndrome elucidates the efficacy of medications such as anticholinergics (eg, trihexyphenidyl), dopamine antagonists (eg, tiapride and tetrabenazine), and GABA receptor agonists (eg, benzodiazepines) in managing these symptoms.<xref ref-type="bibr" rid="article-24919.r4">[4]</xref>&#x000a0;</p>
        <p>Additional medications for Meige syndrome management include antiepileptics (eg, valproic acid) and various psychoactive drugs. Eszopiclone and nitrazepam target specific subunits (omega-1 and omega-2) of the GABA receptor complex, thereby offering relief from eyelid spasms. Case reports suggest zolpidem's efficacy due to its high specificity for the GABA omega-1 receptor. Prolonged use of psychoactive drugs may induce eyelid spasming, which is more often associated with the use of typical antipsychotics, although reports also indicate blepharospasm worsening with olanzapine use.<xref ref-type="bibr" rid="article-24919.r53">[53]</xref></p>
        <p>Botulinum toxin injections represent an effective treatment option for blepharospasm and facial dystonia (see&#x000a0;<bold>Image.</bold> Botulinum Toxin Injections for Blepharospasm).<xref ref-type="bibr" rid="article-24919.r54">[54]</xref> Botulinum A (also known as onabotulinumtoxinA or abobotulinumtoxinA) injections have demonstrated promising outcomes, particularly for patients with inadequate responses to oral medications or experiencing adverse effects from these medications.<xref ref-type="bibr" rid="article-24919.r55">[55]</xref> Afflicted muscles receive botulinum toxin type A injections to induce temporary chemical denervation and reduce muscular hyperactivity.<xref ref-type="bibr" rid="article-24919.r56">[56]</xref>&#x000a0;Treatment typically occurs every 2 to 6 months and depends on an individual's response and the degree of symptoms.<xref ref-type="bibr" rid="article-24919.r57">[57]</xref> However, prolonged and recurrent use of botulinum A injections may lead to therapeutic resistance due to antibody production.<xref ref-type="bibr" rid="article-24919.r58">[58]</xref> Moreover, botulinum toxin injections can result in nearby muscle weakness or exacerbate existing dysphagia or dysarthria.<xref ref-type="bibr" rid="article-24919.r59">[59]</xref></p>
        <p>Deep brain stimulation (DBS) is a consideration for patients unresponsive to noninvasive treatments.<xref ref-type="bibr" rid="article-24919.r60">[60]</xref> This surgical technique involves implanting electrodes into specific brain regions, such as the subthalamic nucleus or globus pallidus internus, to modulate neural activity and reduce dystonic symptoms.<xref ref-type="bibr" rid="article-24919.r61">[61]</xref> Patients with severe, refractory Meige syndrome, inadequately responsive to medical treatments or botulinum toxin injections, may be suitable candidates for this intervention. When botulinum toxin and other conservative treatments fail to produce the desired results, DBS of the globus pallidus interna emerges as an effective option.<xref ref-type="bibr" rid="article-24919.r62">[62]</xref> Electrode placement is meticulously planned, targeting the ventral and posterior segments of the globus pallidus interna, as these areas correspond to the facial region, while the cervicofacial area is situated more anteriorly.<xref ref-type="bibr" rid="article-24919.r63">[63]</xref></p>
        <p>Surgery can be an option for certain cases unresponsive to medical or local therapy, aiming to enhance both functional and aesthetic outcomes (see&#x000a0;<bold>Image.</bold> Limited Myectomy for Blepharospasm).<xref ref-type="bibr" rid="article-24919.r64">[64]</xref> Research indicates that blepharoplasty correction, coupled with selective myectomy and myotomy, can yield lasting improvements for patients with refractory Meige syndrome.<xref ref-type="bibr" rid="article-24919.r65">[65]</xref><xref ref-type="bibr" rid="article-24919.r66">[66]</xref><xref ref-type="bibr" rid="article-24919.r67">[67]</xref></p>
      </sec>
      <sec id="article-24919.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>When evaluating patients with symptoms indicative of Meige syndrome, clinicians should consider a broad range of potential differential diagnoses, including:</p>
        <list list-type="bullet">
          <list-item>
            <p>Xeromas</p>
          </list-item>
          <list-item>
            <p>Spinocerebellar ataxia</p>
          </list-item>
          <list-item>
            <p>Progressive supranuclear palsy</p>
          </list-item>
          <list-item>
            <p>Tardive dyskinesia</p>
          </list-item>
          <list-item>
            <p>Wilson disease</p>
          </list-item>
          <list-item>
            <p>Ischemic stroke</p>
          </list-item>
          <list-item>
            <p>Autoimmune or inflammatory conditions (such as multiple sclerosis, lupus erythematosus, and Beh&#x000e7;et disease)</p>
          </list-item>
          <list-item>
            <p>Metabolic disorders (such as hypoxia and pontine myelinolysis)</p>
          </list-item>
          <list-item>
            <p>Neoplasms (such as meningioma and metastatic tumors)</p>
          </list-item>
          <list-item>
            <p>Myoclonus-dystonia syndrome</p>
          </list-item>
          <list-item>
            <p>Facial tic disorders</p>
          </list-item>
          <list-item>
            <p>Psychogenic craniocervical dystonia</p>
          </list-item>
          <list-item>
            <p>Parkinson disease</p>
          </list-item>
          <list-item>
            <p>Hemifacial spasm</p>
          </list-item>
          <list-item>
            <p>Generalized anxiety disorder</p>
          </list-item>
          <list-item>
            <p>Secondary dystonias</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24919.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis for patients with Meige syndrome varies depending on the severity of symptoms, treatment response, and underlying etiological factors. Although Meige syndrome is a chronic illness that can significantly and negatively influence an individual's quality of life, many patients experience symptom improvement with appropriate management.</p>
        <p>The spectrum of dystonic symptoms in patients with Meige syndrome ranges from mild to severe, with some experiencing sporadic or intermittent contractions, whereas others endure incapacitating symptoms persistently. The degree of functional impairment and its effect on daily activities can impact treatment success and overall prognosis.</p>
        <p>The prognosis of Meige syndrome is influenced by the effectiveness of treatments such as medications, botulinum toxin injections, and surgery. While botulinum toxin injections can alleviate muscular hyperactivity and improve motor function for many patients, individual responses to treatment may vary. Some individuals may require combination therapy or adjustments to their treatment regimen to achieve optimal results.</p>
        <p>Although the progression of Meige syndrome can vary among individuals, it is generally considered a stable or slowly progressing condition. Some&#x000a0;individuals may experience a gradual worsening of symptoms over time, but others may maintain stable symptoms. Close monitoring of patients' disease trajectories and their responses to treatment is essential for optimizing long-term outcomes and implementing any necessary adjustments to their management plans.</p>
        <p>The prognosis of patients with&#x000a0;Meige syndrome may also be affected by underlying genetic, metabolic, or anatomical issues. Unlike idiopathic forms of dystonia, secondary dystonias associated with neurodegenerative diseases, metabolic abnormalities, or structural lesions may have a less favorable outlook. Therefore, it is crucial to identify and address any underlying etiological causes to guide treatment decisions and manage prognostic expectations effectively.</p>
        <p>With the proper care and support, many patients with Meige syndrome can achieve an acceptable quality of life despite the chronic nature of their condition. Multidisciplinary treatments, such as medical therapy, botulinum toxin injections, physical therapy, and supportive interventions, might help reduce symptoms, improve functional results, and enhance overall well-being.</p>
      </sec>
      <sec id="article-24919.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Similar to other types of dystonia, Meige syndrome can result in multiple issues that affect an individual's social, psychological, and physical health. These&#x000a0;adverse effects may arise from the chronic and debilitating nature of the condition and its impact on daily functioning and overall quality of life.</p>
        <p>Common complications of Meige syndrome include functional impairment, pain or discomfort, challenges with speech and swallowing, social isolation and stigma, psychological morbidity, adverse reactions to&#x000a0;medications, and treatment-related outcomes. The social, psychological, and physical ramifications of Meige syndrome can significantly diminish the quality of life for both patients and their caregivers. Implementing a comprehensive, multidisciplinary approach that integrates medical treatment, rehabilitative interventions, psychological support, and social assistance is essential for effectively managing this condition. Strategies aiming to minimize complications, optimize functional outcomes, and enhance overall well-being can substantially improve the lives of those affected by Meige syndrome.&#x000a0;</p>
      </sec>
      <sec id="article-24919.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Empowering patients with comprehensive information about their condition is vital for addressing Meige syndrome care, promoting treatment adherence, and minimizing complications. Effective patient education involves thorough discussions about symptoms, causes, potential impacts on daily life, available treatments, and coping strategies. This fosters informed decision-making and active engagement in their care journey.</p>
        <p>Patients should be informed about the pathophysiology underlying Meige syndrome, including how abnormalities in neurotransmitters contribute to dystonic symptoms and the operation of dysfunctional basal ganglia-thalamocortical circuits. Clear explanations of the biological causes of a patient's ailment might help dispel myths and give them a sense of control over their health. Affected individuals should&#x000a0;understand&#x000a0;the distinctive signs and symptoms of Meige syndrome, such as discomfort, trouble speaking, functional impairment, and involuntary muscle spasms in the face, jaw, and neck.&#x000a0;Encouraging awareness of symptoms and prompt reporting to healthcare professionals can facilitate early identification and intervention.</p>
        <p>Patients should actively participate in discussions about the various treatment options for Meige syndrome, including botulinum toxin injections, surgery, supportive therapy, and oral medications. Each treatment approach has its own benefits and drawbacks, so involving patients in shared decision-making regarding their care is essential. This process should consider their individual treatment goals and preferences, ensuring that the chosen approach aligns with their unique treatment objectives and preferences.</p>
        <p>Patients receiving botulinum toxin injections should receive&#x000a0;thorough education about the treatment process, including how the toxin works, expected benefits, potential adverse effects, and the injection procedure itself. Additionally, it is important to provide guidance to patients on post-injection care, such as scheduling follow-up appointments for additional injections if necessary and monitoring for any signs of muscle weakness or adverse reactions.&#x000a0;</p>
        <p>Patients undergoing treatment for Meige syndrome should understand the significance of adhering to their treatment plans, which should include follow-up appointments, performing physical therapy exercises, and adhering to medication schedules. Medication&#x000a0;adverse effects, budgetary limitations, or practical challenges can hinder treatment adherence, potentially compromising treatment effectiveness and exacerbating the condition. Addressing these obstacles is essential to optimize treatment outcomes and prevent worsening of the condition.</p>
        <p>Motivating patients to adopt a healthy lifestyle is crucial as it can aid in symptom management and overall well-being for individuals with Meige syndrome. This may involve strategies to reduce stress, maintain regular exercise, prioritize adequate rest, and receive dietary guidance. Additionally, for some patients, avoiding known triggers such as alcohol or caffeine&#x000a0;might prove beneficial. Equipping patients with the resources to actively participate in managing their condition involves tracking symptoms, noting medication effects, and developing coping strategies for dystonic movements and associated challenges.</p>
        <p>Patients can empower themselves by mastering symptom management techniques such as adjusting posture, utilizing sensory tricks, and practicing relaxation exercises. Addressing the emotional and social aspects of Meige syndrome involves encouraging patients to seek support from healthcare professionals, support groups, or counseling services. Engaging in networking and peer support opportunities can provide encouragement, solidarity, and practical advice for navigating the condition's psychosocial challenges.</p>
      </sec>
      <sec id="article-24919.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Managing the complexities of Meige syndrome effectively demands a nuanced approach. Clinical pearls provide invaluable insights for healthcare professionals navigating the complexities of managing this challenging neurological disorder, from early recognition to tailored treatment plans and comprehensive patient education.</p>
        <list list-type="bullet">
          <list-item>
            <p>Identifying hallmark symptoms, such as blepharospasm and oromandibular dystonia, promptly can facilitate timely diagnosis and intervention.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Tailoring treatment plans, which may include botulinum toxin injections and DBS, to each patient's specific requirements and responses is paramount.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Monitoring symptoms, treatment responses, and potential adverse effects regularly is crucial for the long-term management of Meige syndrome, as it allows for adjustments to treatment strategies as needed.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Adopting additional therapies, such as physical and&#x000a0;speech therapies and psychological support, can enhance patients' quality of life and functional outcomes.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Involving multidisciplinary healthcare providers such as neurologists, ophthalmologists, rehabilitation therapists, and speech therapists can help coordinate&#x000a0;care and maximize patient outcomes.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Counseling patients about potential treatment-related&#x000a0;adverse effects, such as weakness or worsening of dysphagia, helps manage expectations and minimize complications.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Providing comprehensive education on the condition, treatment options, and potential complications empowers patients to actively participate in their care.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24919.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Patients with Meige syndrome benefit most from an interprofessional approach involving primary care clinicians, neurologists, neurosurgeons, pharmacists, nurses, social workers, and other healthcare professionals. Early&#x000a0;intervention in patients with Meige syndrome is imperative for reducing morbidity and&#x000a0;optimizing patient outcomes. Current treatment options for Meige syndrome include oral medication, botulinum toxin, DBS, and surgery in nonrespondent cases. Nurses are critical in patient education and facilitating communication within the team. Pharmacists&#x000a0;review causative and therapeutic&#x000a0;medications, check for drug interactions, and provide guidance on administration.</p>
        <p>Evidence-based&#x000a0;strategies&#x000a0;maximize treatment plans and reduce&#x000a0;adverse effects. Ethical principles guide treatment decisions and management, ensuring patient autonomy and informed consent. All healthcare professionals must understand their roles in promoting a multidisciplinary approach to patient care. Interprofessional communication facilitates smooth information sharing and cooperative decision-making within the team. Comprehensive care coordination is vital for seamlessly managing a patient's journey from diagnosis through treatment and follow-up, enhancing patient safety, and minimizing errors. By prioritizing principles of skill, strategy, ethics, interprofessional communication, and care coordination, healthcare professionals&#x000a0;can deliver patient-centered care,&#x000a0;leading to improved patient outcomes and heightened team performance.</p>
      </sec>
      <sec id="article-24919.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24919&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24919">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/neurology/meige-syndrome/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=24919">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24919/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24919">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-24919.s16">
        <fig id="article-24919.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Typical Blepharospasm. This video illustrates a typical case of blepharospasm, characterized by an increased blink rate and intermittent but random squeezing of the eyelids and periorbital tissues. An overaction of the corrugator, procerus, and orbicularis muscles can be seen. In addition, the presence of brow ptosis, ptosis, and dermatochalasis can be observed, which are all exacerbated by the blepharospasm. Contributed by BCK Patel, MD, FRCS</p>
          </caption>
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Blepharospasm-.mp4" mime-subtype="mp4" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-24919.s17">
        <fig id="article-24919.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Botulinum Toxin Injections for Blepharospasm. Botulinum toxin injections may be administered at various sites, as depicted in the image. The dosage varies depending on the severity of the blepharospasm and apraxia of eyelid opening at each specific point. Pretarsal injections are administered to specifically counteract apraxia of eyelid opening. Injections just lateral to the lateral nasal wall aim to alleviate the squeezing of the nasalis muscle, which is observed in some patients. Injections into the corrugator and procerus muscles reduce the downward movement of the brow, consequently aiding eyelid control. Injections just below the brows provide a chemical lift to the brows, thereby improving the ability to open the eyelids. Caution is warranted to inject a minimal amount over the zygomaticus major and minor muscles to prevent the appearance of lower facial weakness following injections. Contributed by BCK Patel, MD, FRCS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Botox__injection__sites" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-24919.s18">
        <fig id="article-24919.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Limited Myectomy for Blepharospasm. The upper eyelid orbital and preseptal orbicularis muscle are dissected from the skin through an eyelid crease incision. The degree to which the pretarsal muscle is removed is determined by the extent of apraxia of eyelid opening (A). Care is exercised to safeguard the skin through meticulous dissection (B). The image illustrates en bloc removal of the orbicularis muscle (C). Contributed by BCK Patel, MD, FRCS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Myectomy" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-24919.s19">
        <title>References</title>
        <ref id="article-24919.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Mao</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ling</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Predictive factors for long-term clinical outcomes of deep brain stimulation in the treatment of primary Meige syndrome.</article-title>
            <source>J Neurosurg</source>
            <year>2020</year>
            <month>May</month>
            <day>01</day>
            <volume>132</volume>
            <issue>5</issue>
            <fpage>1367</fpage>
            <page-range>1367-1375</page-range>
            <pub-id pub-id-type="pmid">30952124</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marion</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Henry Meige: The man and his understanding of dystonia, at the turn of the 19th to 20th century.</article-title>
            <source>Rev Neurol (Paris)</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>178</volume>
            <issue>6</issue>
            <fpage>532</fpage>
            <page-range>532-538</page-range>
            <pub-id pub-id-type="pmid">34799079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tolosa</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kulisevsky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fahn</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Meige syndrome: primary and secondary forms.</article-title>
            <source>Adv Neurol</source>
            <year>1988</year>
            <volume>50</volume>
            <fpage>509</fpage>
            <page-range>509-15</page-range>
            <pub-id pub-id-type="pmid">2899953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>LeDoux</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Meige syndrome: what's in a name?</article-title>
            <source>Parkinsonism Relat Disord</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>15</volume>
            <issue>7</issue>
            <fpage>483</fpage>
            <page-range>483-9</page-range>
            <pub-id pub-id-type="pmid">19457699</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sellal</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Frismand</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cervico-facial dystonia as depicted in sculpture before its scientific description.</article-title>
            <source>Rev Neurol (Paris)</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>175</volume>
            <issue>3</issue>
            <fpage>198</fpage>
            <page-range>198-200</page-range>
            <pub-id pub-id-type="pmid">30658849</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aires</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gomes</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Linhares</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cunha</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rosas</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Vaz</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The impact of deep brain stimulation on health related quality of life and disease-specific disability in Meige Syndrome (MS).</article-title>
            <source>Clin Neurol Neurosurg</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>171</volume>
            <fpage>53</fpage>
            <page-range>53-57</page-range>
            <pub-id pub-id-type="pmid">29807200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jana</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Barik</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Arora</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Current use of medical eponyms--a need for global uniformity in scientific publications.</article-title>
            <source>BMC Med Res Methodol</source>
            <year>2009</year>
            <month>Mar</month>
            <day>09</day>
            <volume>9</volume>
            <fpage>18</fpage>
            <pub-id pub-id-type="pmid">19272131</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ayesu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carlan</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The case for consistent use of medical eponyms by eliminating possessive forms.</article-title>
            <source>J Med Libr Assoc</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>106</volume>
            <issue>1</issue>
            <fpage>127</fpage>
            <page-range>127-129</page-range>
            <pub-id pub-id-type="pmid">29339943</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lurie</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Meigs' syndrome: the history of the eponym.</article-title>
            <source>Eur J Obstet Gynecol Reprod Biol</source>
            <year>2000</year>
            <month>Oct</month>
            <volume>92</volume>
            <issue>2</issue>
            <fpage>199</fpage>
            <page-range>199-204</page-range>
            <pub-id pub-id-type="pmid">10996681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zheng</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lv</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hao</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Bilateral Pallidal Deep Brain Stimulation in Meige Syndrome: Effects on Motor Function, Neuropsychological Status, and Mood.</article-title>
            <source>Neurosurgery</source>
            <year>2023</year>
            <month>May</month>
            <day>01</day>
            <volume>92</volume>
            <issue>5</issue>
            <fpage>1073</fpage>
            <page-range>1073-1079</page-range>
            <pub-id pub-id-type="pmid">36728352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eftekhari</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Choe</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Vagefi</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Gausas</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Eckstein</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Oral methylphenidate for the treatment of refractory facial dystonias.</article-title>
            <source>Ophthalmic Plast Reconstr Surg</source>
            <year>2015</year>
            <season>May-Jun</season>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>e65</fpage>
            <page-range>e65-6</page-range>
            <pub-id pub-id-type="pmid">25951177</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Younce</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Cascella</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Berman</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Jinnah</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Bellows</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Feuerstein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wagle Shukla</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mahajan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>FCF</given-names>
              </name>
              <name>
                <surname>Duque</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Reich</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Deik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stover</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Luna</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Norris</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Anatomical categorization of isolated non-focal dystonia: novel and existing patterns using a data-driven approach.</article-title>
            <source>Dystonia</source>
            <year>2023</year>
            <volume>2</volume>
            <pub-id pub-id-type="pmid">37920445</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balint</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bhatia</surname>
                <given-names>KP</given-names>
              </name>
            </person-group>
            <article-title>Dystonia: an update on phenomenology, classification, pathogenesis and treatment.</article-title>
            <source>Curr Opin Neurol</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>27</volume>
            <issue>4</issue>
            <fpage>468</fpage>
            <page-range>468-76</page-range>
            <pub-id pub-id-type="pmid">24978640</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pedrero-Escalas</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-L&#x000f3;pez</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Santiago-P&#x000e9;rez</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vivancos</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gavil&#x000e1;n</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Clinical experience with patients with spasmodic dysphonia and primary Meige syndrome.</article-title>
            <source>Acta Otorrinolaringol Esp (Engl Ed)</source>
            <year>2019</year>
            <season>Jan-Feb</season>
            <volume>70</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-5</page-range>
            <pub-id pub-id-type="pmid">29716720</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jochim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Gora-Stahlberg</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mantel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Berndt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Castrop</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dresel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Haslinger</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Altered functional connectivity in blepharospasm/orofacial dystonia.</article-title>
            <source>Brain Behav</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>e00894</fpage>
            <pub-id pub-id-type="pmid">29568690</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Horisawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ochiai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Goto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nakajima</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takeda</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kawamata</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Taira</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Long-term outcome of pallidal stimulation for Meige syndrome.</article-title>
            <source>J Neurosurg</source>
            <year>2019</year>
            <month>Jan</month>
            <day>01</day>
            <volume>130</volume>
            <issue>1</issue>
            <fpage>84</fpage>
            <page-range>84-89</page-range>
            <pub-id pub-id-type="pmid">29350600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumar</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Lohmann</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Masuho</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Miyamoto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ferbert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lohnau</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kasten</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hagenah</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Br&#x000fc;ggemann</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Graf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>M&#x000fc;nchau</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kostic</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>Sue</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Domingo</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Rosales</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>LV</given-names>
              </name>
              <name>
                <surname>Freimann</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Westenberger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mukai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kawarai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kaji</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Martemyanov</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Mutations in GNAL: a novel cause of craniocervical dystonia.</article-title>
            <source>JAMA Neurol</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>71</volume>
            <issue>4</issue>
            <fpage>490</fpage>
            <page-range>490-4</page-range>
            <pub-id pub-id-type="pmid">24535567</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koptielow</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Szy&#x00142;ak</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Szewczyk-Roszczenko</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Roszczenko</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kochanowicz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ku&#x00142;akowska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chor&#x00105;&#x0017c;y</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Genetic Update and Treatment for Dystonia.</article-title>
            <source>Int J Mol Sci</source>
            <year>2024</year>
            <month>Mar</month>
            <day>22</day>
            <volume>25</volume>
            <issue>7</issue>
            <pub-id pub-id-type="pmid">38612382</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sarva</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rodriguez-Porcel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rivera</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Barkan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tripathi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gatto</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ruiz</surname>
                <given-names>PG</given-names>
              </name>
              <collab>Rare Movement Disorders Study Group of the International Parkinsons and Movement Disorders Society</collab>
            </person-group>
            <article-title>The role of genetics in the treatment of dystonia with deep brain stimulation: Systematic review and Meta-analysis.</article-title>
            <source>J Neurol Sci</source>
            <year>2024</year>
            <month>Apr</month>
            <day>15</day>
            <volume>459</volume>
            <fpage>122970</fpage>
            <pub-id pub-id-type="pmid">38520940</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arzul</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Henoux</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marion</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Corre</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>[Bilateral chronic dislocation of the temporomandibular joints and Meige syndrome].</article-title>
            <source>Rev Stomatol Chir Maxillofac Chir Orale</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>116</volume>
            <issue>2</issue>
            <fpage>106</fpage>
            <page-range>106-10</page-range>
            <pub-id pub-id-type="pmid">25742702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gautam</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bhatia</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rathi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Meige's syndrome.</article-title>
            <source>Ind Psychiatry J</source>
            <year>2016</year>
            <season>Jul-Dec</season>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>232</fpage>
            <page-range>232-233</page-range>
            <pub-id pub-id-type="pmid">28659707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nag</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Management of Oromandibular Dystonia: A Case Report and Literature Update.</article-title>
            <source>Case Rep Dent</source>
            <year>2017</year>
            <volume>2017</volume>
            <fpage>3514393</fpage>
            <pub-id pub-id-type="pmid">28706744</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Riordan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Raymond</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Saunders-Pullman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bressman</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Daly</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hutchinson</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Age at onset as a factor in determining the phenotype of primary torsion dystonia.</article-title>
            <source>Neurology</source>
            <year>2004</year>
            <month>Oct</month>
            <day>26</day>
            <volume>63</volume>
            <issue>8</issue>
            <fpage>1423</fpage>
            <page-range>1423-6</page-range>
            <pub-id pub-id-type="pmid">15505159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scorr</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Kilic-Berkmen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>McKay</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Hallett</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Baumer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Berman</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Feuerstein</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Perlmutter</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Berardelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ferrazzano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wagle-Shukla</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Malaty</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Jankovic</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bellows</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Barbano</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Vidailhet</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Roze</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bonnet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mahajan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>LeDoux</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Fung</surname>
                <given-names>VSC</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>FCF</given-names>
              </name>
              <name>
                <surname>Defazio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ercoli</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Factor</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wojno</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jinnah</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>Clinical Features and Evolution of Blepharospasm: A Multicenter International Cohort and Systematic Literature Review.</article-title>
            <source>Dystonia</source>
            <year>2022</year>
            <volume>1</volume>
            <pub-id pub-id-type="pmid">36248010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pandey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Meige's syndrome: History, epidemiology, clinical features, pathogenesis and treatment.</article-title>
            <source>J Neurol Sci</source>
            <year>2017</year>
            <month>Jan</month>
            <day>15</day>
            <volume>372</volume>
            <fpage>162</fpage>
            <page-range>162-170</page-range>
            <pub-id pub-id-type="pmid">28017205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Defazio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Abbruzzese</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Livrea</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Berardelli</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of primary dystonia.</article-title>
            <source>Lancet Neurol</source>
            <year>2004</year>
            <month>Nov</month>
            <volume>3</volume>
            <issue>11</issue>
            <fpage>673</fpage>
            <page-range>673-8</page-range>
            <pub-id pub-id-type="pmid">15488460</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <collab>Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group</collab>
            <article-title>A prevalence study of primary dystonia in eight European countries.</article-title>
            <source>J Neurol</source>
            <year>2000</year>
            <month>Oct</month>
            <volume>247</volume>
            <issue>10</issue>
            <fpage>787</fpage>
            <page-range>787-92</page-range>
            <pub-id pub-id-type="pmid">11127535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Defazio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Livrea</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of primary blepharospasm.</article-title>
            <source>Mov Disord</source>
            <year>2002</year>
            <month>Jan</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-12</page-range>
            <pub-id pub-id-type="pmid">11835433</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jankovic</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Orman</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Blepharospasm: demographic and clinical survey of 250 patients.</article-title>
            <source>Ann Ophthalmol</source>
            <year>1984</year>
            <month>Apr</month>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>371</fpage>
            <page-range>371-6</page-range>
            <pub-id pub-id-type="pmid">6144283</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Bilateral deep brain stimulation of the subthalamic nucleus in primary Meige syndrome.</article-title>
            <source>J Neurosurg</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>128</volume>
            <issue>3</issue>
            <fpage>897</fpage>
            <page-range>897-902</page-range>
            <pub-id pub-id-type="pmid">28548593</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cabuk</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Coban</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yalcinkaya Cakir</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sezal Serefoglu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Asik Nacaroglu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ozturk Karabulut</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fazil</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Histopathological View of Benign Essential Blepharospasm: Orbicularis Oculi Hormone Receptor Levels.</article-title>
            <source>Beyoglu Eye J</source>
            <year>2023</year>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>110</fpage>
            <page-range>110-114</page-range>
            <pub-id pub-id-type="pmid">37521878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ma</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Qu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Shu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Qu</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>Blepharospasm, Oromandibular Dystonia, and Meige Syndrome: Clinical and Genetic Update.</article-title>
            <source>Front Neurol</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>630221</fpage>
            <pub-id pub-id-type="pmid">33854473</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jankovic</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Orman</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias.</article-title>
            <source>Neurology</source>
            <year>1988</year>
            <month>Mar</month>
            <volume>38</volume>
            <issue>3</issue>
            <fpage>391</fpage>
            <page-range>391-4</page-range>
            <pub-id pub-id-type="pmid">3279337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yoshimura</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kakihara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Soya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ueda</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Shinkai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Effect of clonazepam treatment on antipsychotic drug-induced Meige syndrome and changes in plasma levels of GABA, HVA, and MHPG during treatment.</article-title>
            <source>Psychiatry Clin Neurosci</source>
            <year>2001</year>
            <month>Oct</month>
            <volume>55</volume>
            <issue>5</issue>
            <fpage>543</fpage>
            <page-range>543-6</page-range>
            <pub-id pub-id-type="pmid">11555353</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>KG</given-names>
              </name>
            </person-group>
            <article-title>Sulpiride in Meige's syndrome: possible role of glutamate.</article-title>
            <source>Yonsei Med J</source>
            <year>1988</year>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>62</fpage>
            <page-range>62-5</page-range>
            <pub-id pub-id-type="pmid">2898184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Piccinin</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Piovesana</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Guimar&#x000e3;es</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>De Campos</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Rezende</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Campos</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Amato-Filho</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Fran&#x000e7;a</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Lopes-Cendes</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Cendes</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>D'Abreu</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Diffuse decreased gray matter in patients with idiopathic craniocervical dystonia: a voxel-based morphometry study.</article-title>
            <source>Front Neurol</source>
            <year>2014</year>
            <volume>5</volume>
            <fpage>283</fpage>
            <pub-id pub-id-type="pmid">25620953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valls-Sole</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Defazio</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Blepharospasm: Update on Epidemiology, Clinical Aspects, and Pathophysiology.</article-title>
            <source>Front Neurol</source>
            <year>2016</year>
            <volume>7</volume>
            <fpage>45</fpage>
            <pub-id pub-id-type="pmid">27064462</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Si</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>DYT-<italic>TOR1A</italic> dystonia: an update on pathogenesis and treatment.</article-title>
            <source>Front Neurosci</source>
            <year>2023</year>
            <volume>17</volume>
            <fpage>1216929</fpage>
            <pub-id pub-id-type="pmid">37638318</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Phan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Ellisman</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Veatch</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Barmada</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Pappas</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Dauer</surname>
                <given-names>WT</given-names>
              </name>
            </person-group>
            <article-title>TorsinA is essential for the timing and localization of neuronal nuclear pore complex biogenesis.</article-title>
            <source>bioRxiv</source>
            <year>2023</year>
            <month>Apr</month>
            <day>27</day>
            <pub-id pub-id-type="pmid">37162852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pandey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bhattad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dinesh</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Tremor in Primary Monogenic Dystonia.</article-title>
            <source>Curr Neurol Neurosci Rep</source>
            <year>2021</year>
            <month>Jul</month>
            <day>15</day>
            <volume>21</volume>
            <issue>9</issue>
            <fpage>48</fpage>
            <pub-id pub-id-type="pmid">34264428</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xue</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Xing</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Pallidal versus subthalamic deep brain stimulation for Meige syndrome: A systematic review and meta-analysis.</article-title>
            <source>Heliyon</source>
            <year>2024</year>
            <month>Mar</month>
            <day>30</day>
            <volume>10</volume>
            <issue>6</issue>
            <fpage>e27945</fpage>
            <pub-id pub-id-type="pmid">38510025</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peckham</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Lopez</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shamim</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Sanku</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Malkani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Stacy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mahant</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Crawley</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Singleton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hallett</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Clinical features of patients with blepharospasm: a report of 240 patients.</article-title>
            <source>Eur J Neurol</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>382</fpage>
            <page-range>382-6</page-range>
            <pub-id pub-id-type="pmid">20649903</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Broussolle</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Laurencin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bernard</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Thobois</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Danaila</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Krack</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Early Illustrations of Geste Antagoniste in Cervical and Generalized Dystonia.</article-title>
            <source>Tremor Other Hyperkinet Mov (N Y)</source>
            <year>2015</year>
            <volume>5</volume>
            <fpage>332</fpage>
            <pub-id pub-id-type="pmid">26417535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marsden</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Blepharospasm-oromandibular dystonia syndrome (Brueghel's syndrome). A variant of adult-onset torsion dystonia?</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>1976</year>
            <month>Dec</month>
            <volume>39</volume>
            <issue>12</issue>
            <fpage>1204</fpage>
            <page-range>1204-9</page-range>
            <pub-id pub-id-type="pmid">1011031</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mao</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Ling</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Cerebellar gray matter alterations predict deep brain stimulation outcomes in Meige syndrome.</article-title>
            <source>Neuroimage Clin</source>
            <year>2023</year>
            <volume>37</volume>
            <fpage>103316</fpage>
            <pub-id pub-id-type="pmid">36610311</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Miao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Muheremu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zuo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Application of electrophysiological methods&#x000a0;and magnetic resonance tomographic angiography in the differentiation between hemifacial spasm and Meige syndrome.</article-title>
            <source>Neurol Sci</source>
            <year>2016</year>
            <month>May</month>
            <volume>37</volume>
            <issue>5</issue>
            <fpage>769</fpage>
            <page-range>769-75</page-range>
            <pub-id pub-id-type="pmid">26838523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Qu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Shu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Gong</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Qu</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Genetic screening in patients of Meige syndrome and blepharospasm.</article-title>
            <source>Neurol Sci</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>43</volume>
            <issue>6</issue>
            <fpage>3683</fpage>
            <page-range>3683-3694</page-range>
            <pub-id pub-id-type="pmid">35044558</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Mutation of ADCY5 gene in patients with Meige syndrome.</article-title>
            <source>Asian J Surg</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>45</volume>
            <issue>7</issue>
            <fpage>1487</fpage>
            <page-range>1487-1488</page-range>
            <pub-id pub-id-type="pmid">35288007</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Geng</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Association of Serum Uric Acid Levels in Meige's Syndrome.</article-title>
            <source>Front Neurosci</source>
            <year>2021</year>
            <volume>15</volume>
            <fpage>755056</fpage>
            <pub-id pub-id-type="pmid">34658782</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tam&#x000e1;s</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Abrantes</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Valadas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Radics</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Albanese</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tijssen</surname>
                <given-names>MAJ</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Quality and reporting of guidelines on the diagnosis and management of dystonia.</article-title>
            <source>Eur J Neurol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>275</fpage>
            <page-range>275-283</page-range>
            <pub-id pub-id-type="pmid">29053896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jinnah</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Factor</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and treatment of dystonia.</article-title>
            <source>Neurol Clin</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>77</fpage>
            <page-range>77-100</page-range>
            <pub-id pub-id-type="pmid">25432724</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karp</surname>
                <given-names>BI</given-names>
              </name>
            </person-group>
            <article-title>Botulinum toxin physiology in focal hand and cranial dystonia.</article-title>
            <source>Toxins (Basel)</source>
            <year>2012</year>
            <month>Nov</month>
            <day>20</day>
            <volume>4</volume>
            <issue>11</issue>
            <fpage>1404</fpage>
            <page-range>1404-14</page-range>
            <pub-id pub-id-type="pmid">23202323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sobstyl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Z&#x00105;bek</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[Deep brain stimulation in the treatment of torticollis and Meige syndrome].</article-title>
            <source>Neurol Neurochir Pol</source>
            <year>2011</year>
            <season>Nov-Dec</season>
            <volume>45</volume>
            <issue>6</issue>
            <fpage>590</fpage>
            <page-range>590-9</page-range>
            <pub-id pub-id-type="pmid">22212990</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simpson</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Hallett</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ashman</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Comella</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Gronseth</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Gloss</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Potrebic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jankovic</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Karp</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Naumann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>So</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Yablon</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology.</article-title>
            <source>Neurology</source>
            <year>2016</year>
            <month>May</month>
            <day>10</day>
            <volume>86</volume>
            <issue>19</issue>
            <fpage>1818</fpage>
            <page-range>1818-26</page-range>
            <pub-id pub-id-type="pmid">27164716</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hassell</surname>
                <given-names>TJW</given-names>
              </name>
              <name>
                <surname>Charles</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Blepharospasm and Oromandibular Dystonia with Botulinum Toxins.</article-title>
            <source>Toxins (Basel)</source>
            <year>2020</year>
            <month>Apr</month>
            <day>22</day>
            <volume>12</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">32331272</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karp</surname>
                <given-names>BI</given-names>
              </name>
              <name>
                <surname>Alter</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Botulinum Toxin Treatment of Blepharospasm, Orofacial/Oromandibular Dystonia, and Hemifacial Spasm.</article-title>
            <source>Semin Neurol</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>36</volume>
            <issue>1</issue>
            <fpage>84</fpage>
            <page-range>84-91</page-range>
            <pub-id pub-id-type="pmid">26866500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duarte</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Coutinho</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Germiniani</surname>
                <given-names>FMB</given-names>
              </name>
              <name>
                <surname>Teive</surname>
                <given-names>HAG</given-names>
              </name>
            </person-group>
            <article-title>Effects of onabotulinum toxin type A injections in patients with Meige's syndrome.</article-title>
            <source>Arq Neuropsiquiatr</source>
            <year>2024</year>
            <month>Apr</month>
            <volume>82</volume>
            <issue>4</issue>
            <fpage>1</fpage>
            <page-range>1-7</page-range>
            <pub-id pub-id-type="pmid">38641339</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>WQ</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>QL</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>XP</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>WF</given-names>
              </name>
            </person-group>
            <article-title>Association analyses between the variants of <italic>SNAP25</italic>, <italic>SV2C</italic> and <italic>ST3GAL2</italic> and the efficacy of botulinum toxin A in the treatment of the primary Meige syndrome.</article-title>
            <source>Heliyon</source>
            <year>2024</year>
            <month>Apr</month>
            <day>30</day>
            <volume>10</volume>
            <issue>8</issue>
            <fpage>e28543</fpage>
            <pub-id pub-id-type="pmid">38628704</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zheng</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhan</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Effect of botulinum toxin type A on non-motor symptoms and quality of life in Meige syndrome.</article-title>
            <source>Front Neurol</source>
            <year>2023</year>
            <volume>14</volume>
            <fpage>1115482</fpage>
            <pub-id pub-id-type="pmid">36846150</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodrigues</surname>
                <given-names>FB</given-names>
              </name>
              <name>
                <surname>Duarte</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Prescott</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Deep brain stimulation for dystonia.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2019</year>
            <month>Jan</month>
            <day>10</day>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>CD012405</fpage>
            <pub-id pub-id-type="pmid">30629283</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arag&#x000e3;o</surname>
                <given-names>VT</given-names>
              </name>
              <name>
                <surname>Barbosa Casagrande</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Listik</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Teixeira</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Barbosa</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Cury</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Rescue Subthalamic Deep Brain Stimulation for Refractory Meige Syndrome.</article-title>
            <source>Stereotact Funct Neurosurg</source>
            <year>2021</year>
            <volume>99</volume>
            <issue>5</issue>
            <fpage>451</fpage>
            <page-range>451-453</page-range>
            <pub-id pub-id-type="pmid">33895729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Odorfer</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Volkmann</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Deep Brain Stimulation for Focal or Segmental Craniocervical Dystonia in Patients Who Have Failed Botulinum Neurotoxin Therapy-A Narrative Review of the Literature.</article-title>
            <source>Toxins (Basel)</source>
            <year>2023</year>
            <month>Oct</month>
            <day>09</day>
            <volume>15</volume>
            <issue>10</issue>
            <pub-id pub-id-type="pmid">37888637</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Limotai</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Go</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Oyama</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hwynn</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zesiewicz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Foote</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bhidayasiri</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Malaty</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Zeilman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Okun</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Mixed results for GPi-DBS in the treatment of cranio-facial and cranio-cervical dystonia symptoms.</article-title>
            <source>J Neurol</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>258</volume>
            <issue>11</issue>
            <fpage>2069</fpage>
            <page-range>2069-74</page-range>
            <pub-id pub-id-type="pmid">21553081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lai</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Ramachandran</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>YP</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of Blepharoptosis in Patients With Refractory Blepharospasm by VISA-Video Recordings, Idiosyncratic Expressions, Sensory Tricks, and Ancillary Procedures.</article-title>
            <source>Ann Plast Surg</source>
            <year>2023</year>
            <month>May</month>
            <day>01</day>
            <volume>90</volume>
            <issue>5S Suppl 2</issue>
            <fpage>S172</fpage>
            <page-range>S172-S176</page-range>
            <pub-id pub-id-type="pmid">37192418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pariseau</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Worley</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Myectomy for blepharospasm 2013.</article-title>
            <source>Curr Opin Ophthalmol</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>488</fpage>
            <page-range>488-93</page-range>
            <pub-id pub-id-type="pmid">23925062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lai</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Myotomy In Situ for Essential Blepharospasm Refractory to Botulinum Toxin.</article-title>
            <source>Ann Plast Surg</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>84</volume>
            <issue>1S Suppl 1</issue>
            <fpage>S74</fpage>
            <page-range>S74-S79</page-range>
            <pub-id pub-id-type="pmid">31833891</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24919.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lai</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Ramachandran</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>YP</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>MW</given-names>
              </name>
            </person-group>
            <article-title>Selective Myectomy and Myotomy In Situ for the Management of Refractory Blepharospasm in Meige Syndrome.</article-title>
            <source>Ann Plast Surg</source>
            <year>2023</year>
            <month>Apr</month>
            <day>01</day>
            <volume>90</volume>
            <issue>1 Suppl 1</issue>
            <fpage>S84</fpage>
            <page-range>S84-S88</page-range>
            <pub-id pub-id-type="pmid">36752539</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
